de Leeuw Thomas G, der Zanden Tjitske van, Ravera Simona, Felisi Mariagrazia, Bonifazi Donato, Tibboel Dick, Ceci Adriana, Kaguelidou Florentia, de Wildt Saskia N
Department of Pediatric Anesthesia and Pain Medicine, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Intensive Care and Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Children (Basel). 2020 Nov 2;7(11):208. doi: 10.3390/children7110208.
Validated diagnostic tools to diagnose chronic neuropathic and mixed pain in children are missing. Therapeutic options are often derived from therapeutics for adults. To investigate the international practice amongst practitioners for the diagnosis and treatment of chronic, neuropathic pain in children and adolescents, we performed a survey study among members of learned societies or groups whose members are known to treat pediatric pain. The survey included questions concerning practitioners and practice characteristics, assessment and diagnosis, treatment and medication. We analyzed 117 returned questionnaires, of which 41 (35%) were fully completed and 76 (65%) were partially completed. Most respondents based the diagnosis of neuropathic pain on physical examination (68 (58.1%)), patient history (67 (57.3%)), and underlying disease (59 (50.4%)) combined. Gabapentin, amitriptyline, and pregabalin were the first-choice treatments for moderate neuropathic pain. Tramadol, ibuprofen, amitriptyline, and paracetamol were the first-choice treatments for moderate mixed pain. Consensus on the diagnostic process of neuropathic pain in children and adolescents is lacking. Drug treatment varies widely for moderate, severe neuropathic, and mixed pain. Hence, diagnostic tools and therapy need to be harmonized and validated for use in children.
目前缺少经过验证的用于诊断儿童慢性神经性疼痛和混合性疼痛的工具。治疗方案通常借鉴成人的疗法。为了调查从业者在诊断和治疗儿童及青少年慢性神经性疼痛方面的国际实践情况,我们对学术团体或已知治疗儿童疼痛的团体成员进行了一项调查研究。该调查包括有关从业者和实践特征、评估与诊断、治疗与用药的问题。我们分析了117份回收的问卷,其中41份(35%)填写完整,76份(65%)部分填写完整。大多数受访者将神经性疼痛的诊断基于体格检查(68人(58.1%))、患者病史(67人(57.3%))和基础疾病(59人(50.4%))的综合判断。加巴喷丁、阿米替林和普瑞巴林是中度神经性疼痛的首选治疗药物。曲马多、布洛芬、阿米替林和对乙酰氨基酚是中度混合性疼痛的首选治疗药物。对于儿童和青少年神经性疼痛的诊断过程缺乏共识。对于中度、重度神经性疼痛和混合性疼痛,药物治疗差异很大。因此,诊断工具和治疗方法需要统一并验证其在儿童中的适用性。